Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor
暂无分享,去创建一个
E. Lerut | R. Oyen | P. Debruyne | P. Barthélémy | P. Schöffski | B. Beuselinck | S. Joniau | P. Wolter | H. Dumez | C. Korenbaum | A. Sacré | M. Burgy | T. Loyson | Tine Loyson